Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10252
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMinigo, Gabrielaen
dc.contributor.authorScholzen, Anjaen
dc.contributor.authorTang, Choon Ken
dc.contributor.authorHanley, Jennifer Cen
dc.contributor.authorKalkanidis, Marthaen
dc.contributor.authorPietersz, Geoffrey Aen
dc.contributor.authorApostolopoulos, Vassoen
dc.contributor.authorPlebanski, Magdalenaen
dc.date.accessioned2015-05-15T23:38:33Z
dc.date.available2015-05-15T23:38:33Z
dc.date.issued2006-10-10en
dc.identifier.citationVaccine 2006; 25(7): 1316-27en
dc.identifier.govdoc17052812en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10252en
dc.description.abstractDNA formulations provide the basis for safe and cost efficient vaccines. However, naked plasmid DNA is only poorly immunogenic and new effective delivery strategies are needed to enhance the potency of DNA vaccines. In this study, we present a novel approach for the delivery of DNA vaccines using inert poly-L-lysine (PLL) coated polystyrene particles, which greatly enhance DNA immunogenicity. Intradermal injection of plasmid DNA encoding for chicken egg ovalbumin (OVA) complexed with PLL-coated polystyrene nanoparticles induced high levels of CD8 T cells as well as OVA-specific antibodies in C57BL/6 mice and furthermore inhibited tumour growth after challenge with the OVA expressing EG7 tumour cell line. Importantly, vaccine efficacy depended critically on the size of the particles used as well as on the presence of the PLL linker. Our data show that PLL-coated polystyrene nanoparticles of 0.05 microm but not 0.02 microm or 1.0 microm in diameter are highly effective for the delivery of DNA vaccines.en
dc.language.isoenen
dc.subject.otherAdjuvants, Immunologic.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherAntibody Formation.drug effects.immunologyen
dc.subject.otherCD4-Positive T-Lymphocytes.immunologyen
dc.subject.otherCD8-Positive T-Lymphocytes.immunologyen
dc.subject.otherCell Line, Tumoren
dc.subject.otherChemistry, Pharmaceuticalen
dc.subject.otherDendritic Cells.immunologyen
dc.subject.otherDrug Carriersen
dc.subject.otherDrug Delivery Systemsen
dc.subject.otherEnzyme-Linked Immunosorbent Assayen
dc.subject.otherFemaleen
dc.subject.otherImmunity, Cellular.drug effects.immunologyen
dc.subject.otherMacrophages, Peritoneal.immunologyen
dc.subject.otherMiceen
dc.subject.otherMice, Inbred BALB Cen
dc.subject.otherNanoparticlesen
dc.subject.otherNeoplasm Transplantationen
dc.subject.otherNeoplasms.immunology.prevention & controlen
dc.subject.otherOvalbumin.immunologyen
dc.subject.otherParticle Sizeen
dc.subject.otherPlasmids.genetics.immunologyen
dc.subject.otherPolylysine.pharmacologyen
dc.subject.otherPolystyrenesen
dc.subject.otherVaccines, DNA.immunologyen
dc.titlePoly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.en
dc.typeJournal Articleen
dc.identifier.journaltitleVaccineen
dc.identifier.affiliationVaccine and Infectious Diseases Laboratory, The Burnet Institute incorporating the Austin Research Institute, Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australiaen
dc.identifier.doi10.1016/j.vaccine.2006.09.086en
dc.description.pages1316-27en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/17052812en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.